The DOI matches its Crossref record; 260 of the 260 references it cites were found in a registry or an index.
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Open accessAbstract
Tumor cells develop resistance to chemotherapeutic drugs through multiple mechanisms. Overexpression of efflux transporters is an important source of drug resistance. Efflux transporters such as P-glycoprotein reduce intracellular drug accumulation and compromise drug efficacy. Various nanoparticle-based approaches have been investigated to overcome efflux-mediated resistance. These include the use of formulation excipients that inhibit transporter activity and co-delivery of the anticancer drug with a specific inhibitor of transporter function or expression. However, the effectiveness of nanoparticles can be diminished by poor transport in the tumor tissue. Hence, adjunct therapies that improve the intratumoral distribution of nanoparticles may be vital to the successful application of nanotechnology to overcome tumor drug resistance. This review discusses the mechanisms of tumor drug resistance and highlights the opportunities and challenges in the use of nanoparticles to improve the efficacy of anticancer drugs against resistant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–260 of 260
Hagendoorn, J., Tong, R. T., Fukumura, D., Lin, Q., Shah, J. L., Padera, T. P., Xu, L., Kucherlapati, R., & Jain, R. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2655 · Cited by 138
Metastases and the Normalization of Tumour Blood Vessels by ICRF 159: A New Type of Drug Action
Serve, A. W. L., & Hellmann, K. (1972) · BMJ · doi:10.1136/bmj.1.5800.597 · Cited by 137
Peng, K., Cluzeaud, F., Bens, M., Huyen, J. D. V., Wioland, M.-A., Lacave, R., & Vandewalle, A. (1999) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549904700605 · Cited by 137
Green, C. E., Liu, T., Montel, V., Hsiao, G., Lester, R. D., Subramaniam, S., Gonias, S. L., & Klemke, R. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006713 · Cited by 135
Cerniglia, G. J., Pore, N., Tsai, J. H., Schultz, S. M., Mick, R., Choe, R., Xing, X., Durduran, T., Yodh, A. G., Evans, S. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006539 · Cited by 128
Raghunand, N., Martı́nez–Zaguilán, R., Wright, S. H., & Gillies, R. J. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00021-0 · Cited by 127
Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux
Chavanpatil, M. D., Patil, Y. B., & Panyam, J. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.03.045 · Cited by 124
Self-citationThe Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-α Antitumor Effects
Moserle, L., Indraccolo, S., Ghisi, M., Frasson, C., Fortunato, E., Canevari, S., Miotti, S., Tosello, V., Zamarchi, R., Corradin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6341 · Cited by 123
Åmellem, Ø., & Pettersen, E. O. (1991) · Cell Proliferation · doi:10.1111/j.1365-2184.1991.tb01144.x · Cited by 122
Milane, L. S., Duan, Z., & Amiji, M. M. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-3 · Cited by 122
Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells
de Verdière, A. C., Dubernet, C., Némati, F., Poupon, M., Puisieux, F., & Couvreur, P. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686509 · Cited by 119
McGrath, T., & M S Center (1988) · PubMed · Cited by 117
DNA repair in resistance to alkylating anticancer drugs
Kaina, B., & Christmann, M. (2002) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40354 · Cited by 117
Surfactant–Polymer Nanoparticles Overcome P-Glycoprotein-Mediated Drug Efflux
Chavanpatil, M. D., Khdair, A., Gérard, B., Bachmeier, C. J., Miller, D. W., Shekhar, M. P. V., & Panyam, J. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070024d · Cited by 117
Self-citationMellish, K. J., Kèlland, L. R., & Harrap, K. R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.322 · Cited by 115
Altenberg, G. A., Vanoye, C. G., Horton, J. K., & Reuss, L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4654 · Cited by 113
de Graaf, D., Sharma, R., Mechetner, E. B., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1238 · Cited by 109
Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery
Tailor, T. D., Hanna, G., Yarmolenko, P., Dreher, M. R., Warner, A. B., Nixon, A. B., Spasojević, I., & Dewhirst, M. W. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0856 · Cited by 106
Modulation of doxorubicin resistance in multidrug‐resistant cells by liposomes
Thierry, A. R., Vigé, D., Coughlin, S. S., Belli, J. A., Dritschilo, A., & Rahman, A. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.6.8097173 · Cited by 105
Huang, Y., Snuderl, M., & Jain, R. K. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.005 · Cited by 101
Chavanpatil, M. D., Khdair, A., & Panyam, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9203-2 · Cited by 98
Self-citationInteraction of LDS-751 with P-Glycoprotein and Mapping of the Location of the R Drug Binding Site
Lugo, M. R., & Sharom, F. J. (2005) · Biochemistry · doi:10.1021/bi0485326 · Cited by 98
Hubensack, M., Müller, C., Höcherl, P., Fellner, S., Spruß, T., Bernhardt, G., & Buschauer, A. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0323-9 · Cited by 97
Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung.
Wright, S. R., Boag, A. H., Valdimarsson, G., Hipfner, D. R., Campling, B. G., Cole, S. P. C., & Deeley, R. G. (1998) · PubMed · Cited by 96
Fracasso, P. M., Brady, M. F., Moore, D. H., Walker, J. L., Rose, P. G., Letvak, L. A., Grogan, T. M., & McGuire, W. P. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.2975 · Cited by 95
Bhattacharya, A., Seshadri, M., Oven, S. D., Tóth, K., Vaughan, M. M., & Rustum, Y. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0212 · Cited by 95
Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors.
Rao, P. H., Houldsworth, J., Palanisamy, N., Murty, V. V. V. S., Reuter, V. E., Motzer, R. J., Bosl, G. J., & Chaganti, R. S. K. (1998) · PubMed · Cited by 92
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
Bianco, R., Troiani, T., Tortora, G., & Ciardiello, F. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00999 · Cited by 92
Kuhn, S., Finch, S. K., Hallahan, D. E., & Giorgio, T. D. (2006) · Nano Letters · doi:10.1021/nl052241g · Cited by 88
Oh, K. S., Song, J. Y., Cho, S. H., Lee, B. S., Kim, S. Y., Kim, K., Jeon, H., Kwon, I. C., & Yuk, S. H. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.021 · Cited by 82
Karászi, É., Jakab, K. T., Homolya, L., Szakács, G., Holló, Z., Telek, B., Kiss, A., Rejtő, L., Nahajevszky, S., Sarkadi, B., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02554.x · Cited by 80
Update on angiogenesis inhibitors
Zakarija, A., & Soff, G. A. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000183672.15133.ab · Cited by 78
Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to Tumors
Escorcia, F. E., Henke, E., McDevitt, M. R., Villa, C. H., Smith-Jones, P. M., Blasberg, R. G., Benezra, R., & Scheinberg, D. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2029 · Cited by 78
Ruefli, A. A., Tainton, K. M., Darcy, P. K., Smyth, M. J., & Johnstone, R. W. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401081 · Cited by 76
Song, X. R., Zheng, Y., Zheng, Y., et al. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22200 · Cited by 75
Chintamani, C., Singh, J., Mittal, M. K., et al. (2005) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-3-61 · Cited by 70
Kohno, N., Ohnuma, T., & Truog, P. (1994) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01236386 · Cited by 69
Wasenius, V.-M., Jekunen, A. P., Monni, O. M., Joensuu, H., Aebi, S., Howell, S. B., & Knuutila, S. (1997) · Genes Chromosomes and Cancer · Cited by 65
Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
Vlahovic, G., Ponce, A. M., Rabbani, Z. N., Salahuddin, F. K., Zgonjanin, L., Spasojević, I., Vujaskovic, Z., & Dewhirst, M. W. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603941 · Cited by 63
Inhibition of the genotoxicity of bleomycin by superoxide dismutase
Cunningham, M. L., Ringrose, P. S., & Lokesh, B. R. (1984) · Mutation Research/Genetic Toxicology · doi:10.1016/0165-1218(84)90122-8 · Cited by 59
SMITH, K., Skelton, H. G., Turiansky, G. W., & WAGNER, K. (1997) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(97)70288-3 · Cited by 56
Weisburg, J. H., Roepe, P. D., Dzekunov, S. M., & Scheinberg, D. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10877 · Cited by 55
Brekken, C., & Davies, C. D. L. (1998) · Cancer Letters · doi:10.1016/s0304-3835(98)00202-x · Cited by 53
Brekken, C., Hjelstuen, M., Bruland, Ø. S., & Davies, C. D. L. (2000) · PubMed · Cited by 53
Molecular and pharmacological strategies to overcome multidrug resistance
Shabbits, J. A., Krishna, R., & Mayer, L. D. (2001) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.1.4.585 · Cited by 51
Qayum, N., Im, J. H., Stratford, M. R. L., Bernhard, E. J., McKenna, W. G., & Muschel, R. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1413 · Cited by 48
Maier, U., & Baumgartner, G. (1989) · The Journal of Urology · doi:10.1016/s0022-5347(17)40881-0 · Cited by 47
Yin, M.-B., Li, Z.-R., Tóth, K., Cao, S., Durrani, F. A., Hapke, G., Bhattacharya, A., Azrak, R. G., Frank, C., & Rustum, Y. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209073 · Cited by 44
Zheng, X., Goins, B., Cameron, I. L., Santoyo, C., Bao, A., Frohlich, V. C., & Fullerton, G. D. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1305-1 · Cited by 43
Implications of Cancer Stem Cells In the Treatment of Cancer
Pan, C.-X., Zhu, W. P., & Liang Cheng, C. (2006) · Future Oncology · doi:10.2217/14796694.2.6.723 · Cited by 41
Role of Hypoxia in Photodynamic Therapy of Tumors
Freitas, I. (1985) · Tumori Journal · doi:10.1177/030089168507100306 · Cited by 39
Clary, I., Doherty, G., Morán, E., & CLYNES, M. M. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00003-8 · Cited by 37
Muckenschnabel, I., Bernhardt, G., Spruß, T., & Buschauer, A. (1998) · Cancer Letters · doi:10.1016/s0304-3835(98)00203-1 · Cited by 37
A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
Fakih, M., Pendyala, L., Smith, P. F., Creaven, P. J., Reid, M. E., Badmaev, V., Azrak, R. G., Prey, J. D., Lawrence, D. D., & Rustum, Y. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2004 · Cited by 37
Wang, J., Qu, H. Y., Jin, L., Zeng, W., Qin, L., Zhang, F., Wei, X., Lü, W.-L., Zhang, C., & Liang, W. P. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22461 · Cited by 30
Clinical biomarkers of kinase activity: examples from EGFR inhibition trials
Krause, M., & Baumann, M. A. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9141-z · Cited by 28
Wang, Y., Chen, L., Ding, Y., & Yan, W. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.10.029 · Cited by 20
Serve, A. W. L., & Hellmann, K. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9111-9 · Cited by 8
Roblot-Treupel, L., Poupon, M., Couvreur, P., & Puisieux, F. (1991) · PubMed · Cited by 7
Burgess, D. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3375 · Cited by 1
Cited by
Della Torre, C., Bergami, E., Salvati, A., Faleri, C., Cirino, P., Dawson, K. A., & Corsi, I. (2014) · Environmental Science & Technology · doi:10.1021/es502569w · Cited by 632
Recent advances in functional nanomaterials for light–triggered cancer therapy
Gai, S., Yang, G., Yang, P., He, F., Lin, J., Jin, D., & Xing, B. (2018) · Nano Today · doi:10.1016/j.nantod.2018.02.010 · Cited by 568
Miao, T., Wang, J., Zeng, Y., Liu, G., & Chen, X. (2018) · Advanced Science · doi:10.1002/advs.201700513 · Cited by 362
Chen, L., Zhou, L., Wang, C., Han, Y., Lu, Y., Liu, J., Hu, X., Yao, T., Lin, Y., Liang, S., et al. (2019) · Advanced Materials · doi:10.1002/adma.201904997 · Cited by 337
An O2 Self‐Sufficient Biomimetic Nanoplatform for Highly Specific and Efficient Photodynamic Therapy
Cheng, H., Zhu, J., Li, S., Zeng, J., Lei, Q., Chen, K., Zhang, C., & Zhang, X. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201603212 · Cited by 335
Metadata
- Authors
- Kirtane, A. R., Kalscheuer, S. M., & Panyam, J.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 65
- Issue
- 13-14
- Pages
- 1731-1747
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2050564805
- Cited by
- 258
- References
- 260
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.